RecruitingNCT06353087

Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis (AD) Patients Receiving Abrocitinib

Sponsor

Pfizer

Enrollment

200 participants

Start Date

Jul 1, 2024

Study Type

OBSERVATIONAL

Conditions

Dermatitis Eczema Immune System Diseases Skin Diseases Dermatitis Atopic Janus Kinase Inhibitors

Summary

This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.

Eligibility

Min Age: 12 Years

Inclusion Criteria4

Patients aged ≥12 years
Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician
Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions
Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study

Exclusion Criteria3

Patients meeting any of the following criteria will not be included in the study:
Any prior use of abrocitinib
Simultaneous participation in a study that includes administration of any investigational drug or procedure

Interested in this trial?

Get notified about updates and connect with the research team.